Feb 4 (Reuters) – GSK on Wednesday forecast sales growth to slow in 2026 in the first outlook presented by new CEO Luke Miels as the drugmaker shifts focus on expanding its pipeline to counter looming patent expiries for its top-selling HIV drugs.Â
The firm expects revenue to grow 3 % to 5% this year, at constant currency rates, after rising 7% in 2025.
(Reporting by Sri Hari N S, Pushkala Aripaka in Bengaluru, and Bhanvi Satija in London; Editing by Sonia Cheema)
